• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估类风湿关节炎患者甲氨蝶呤肝毒性的两种方法。

Two methods of assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis.

作者信息

Hall P D, Ahern M J, Jarvis L R, Stoll P, Jenner M A, Harley H

机构信息

Department of Medicine, Flinders University of South Australia.

出版信息

Ann Rheum Dis. 1991 Jul;50(7):471-6. doi: 10.1136/ard.50.7.471.

DOI:10.1136/ard.50.7.471
PMID:1877853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1004460/
Abstract

Serial liver biopsy specimens from 18 patients with rheumatoid arthritis receiving a weekly dose of methotrexate 7.5-20 mg for a minimum of 12 months were assessed semiquantitatively and by a microcomputer image analysis system. The semiquantitative histological method showed a significant increase in pericellular collagen and in overall disease while morphometry showed a significant increase in pericellular, perivenular, and portal tract collagen. There was a significant correlation between the two methods, but morphometry had the advantage of objectivity and efficiency. There was no correlation between the increase in collagen and the accumulated dose of methotrexate, which suggests that other factors in addition to methotrexate may contribute to liver injury.

摘要

对18例类风湿关节炎患者进行了连续肝脏活检,这些患者每周接受7.5 - 20毫克甲氨蝶呤治疗,疗程至少12个月,采用半定量法并通过微机图像分析系统进行评估。半定量组织学方法显示细胞周围胶原和整体病变有显著增加,而形态测量法显示细胞周围、静脉周围和汇管区胶原均有显著增加。两种方法之间存在显著相关性,但形态测量法具有客观性和高效性的优势。胶原增加与甲氨蝶呤累积剂量之间无相关性,这表明除甲氨蝶呤外的其他因素可能导致肝损伤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/91715d5fb3f6/annrheumd00455-0020-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/15803cedd7b1/annrheumd00455-0019-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/2686488869c4/annrheumd00455-0019-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/3b43e5ee0820/annrheumd00455-0020-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/4d4d55619bf4/annrheumd00455-0020-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/f25f3bda8e51/annrheumd00455-0020-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/91715d5fb3f6/annrheumd00455-0020-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/15803cedd7b1/annrheumd00455-0019-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/2686488869c4/annrheumd00455-0019-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/3b43e5ee0820/annrheumd00455-0020-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/4d4d55619bf4/annrheumd00455-0020-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/f25f3bda8e51/annrheumd00455-0020-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2675/1004460/91715d5fb3f6/annrheumd00455-0020-d.jpg

相似文献

1
Two methods of assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis.评估类风湿关节炎患者甲氨蝶呤肝毒性的两种方法。
Ann Rheum Dis. 1991 Jul;50(7):471-6. doi: 10.1136/ard.50.7.471.
2
Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings.肝脏甲氨蝶呤含量与肝纤维化进展:初步研究结果。
Ann Rheum Dis. 1991 Jul;50(7):477-80. doi: 10.1136/ard.50.7.477.
3
Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment.在接受低剂量甲氨蝶呤治疗期间持续性转氨升高的类风湿关节炎患者的肝活检中出现非酒精性脂肪性肝炎样模式。
PLoS One. 2018 Aug 24;13(8):e0203084. doi: 10.1371/journal.pone.0203084. eCollection 2018.
4
Liver biopsies in patients with rheumatoid arthritis receiving methotrexate: where are we going?接受甲氨蝶呤治疗的类风湿关节炎患者的肝脏活检:我们何去何从?
J Rheumatol. 1992 Feb;19(2):189-91.
5
Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio.长期低剂量口服甲氨蝶呤治疗难治性银屑病、银屑病关节炎和类风湿关节炎时肝毒性发生率低。风险/效益比可接受。
Dig Dis Sci. 1985 Feb;30(2):104-9. doi: 10.1007/BF01308193.
6
Hepatotoxicity associated with low-dose, long-term methotrexate treatment of rheumatoid arthritis.低剂量、长期使用甲氨蝶呤治疗类风湿关节炎相关的肝毒性。
Scand J Rheumatol. 1987;16(4):229-34. doi: 10.3109/03009748709102922.
7
Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate.
J Rheumatol. 1989 Apr;16(4):489-93.
8
Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis.甲氨蝶呤长期治疗类风湿关节炎的肝毒性。
Cleve Clin Q. 1985 Summer;52(2):129-35. doi: 10.3949/ccjm.52.2.129.
9
"Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?".甲氨蝶呤每周单次给药联合叶酸治疗类风湿关节炎和银屑病关节炎的肝毒性:真实频率如何?
Ann Hepatol. 2019 Sep-Oct;18(5):765-769. doi: 10.1016/j.aohep.2019.01.011. Epub 2019 May 7.
10
Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis.接受低剂量脉冲甲氨蝶呤治疗类风湿关节炎患者的肝脏组织学
Ann Rheum Dis. 1990 Aug;49(8):591-3. doi: 10.1136/ard.49.8.591.

引用本文的文献

1
Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment.甲氨蝶呤治疗中肝脏纤维化的磁共振弹性成像
Open J Rheumatol Autoimmune Dis. 2012 May;2(2):6-13. doi: 10.4236/ojra.2012.22003.
2
Methotrexate hepatotoxicity in patients with rheumatoid arthritis.类风湿关节炎患者的甲氨蝶呤肝毒性
Middle East J Dig Dis. 2010 Sep;2(2):104-9.
3
Methotrexate in rheumatoid arthritis. An update.类风湿关节炎中的甲氨蝶呤。最新进展。

本文引用的文献

1
Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis.甲氨蝶呤治疗银屑病的并发症,特别提及肝纤维化
J Invest Dermatol. 1982 Oct;79(4):229-32. doi: 10.1111/1523-1747.ep12500067.
2
Collagen production by rat hepatocytes and sinusoidal cells in primary monolayer culture.原代单层培养的大鼠肝细胞和窦状细胞产生胶原蛋白的情况。
Hepatology. 1982 Jan-Feb;2(1):13-8. doi: 10.1002/hep.1840020104.
3
Methotrexate guidelines--revised.
J Am Acad Dermatol. 1982 Feb;6(2):145-55. doi: 10.1016/s0190-9622(82)80064-9.
Drugs. 1994 Jan;47(1):25-50. doi: 10.2165/00003495-199447010-00003.
4
Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings.肝脏甲氨蝶呤含量与肝纤维化进展:初步研究结果。
Ann Rheum Dis. 1991 Jul;50(7):477-80. doi: 10.1136/ard.50.7.477.
4
Hepatotoxic effects of methotrexate.甲氨蝶呤的肝毒性作用。
Cancer. 1966 Apr;19(4):600-6. doi: 10.1002/1097-0142(196604)19:4<600::aid-cncr2820190420>3.0.co;2-3.
5
Fat-storing cells (lipocytes) in human liver.人类肝脏中的贮脂细胞(脂肪细胞)。
Arch Pathol. 1966 Nov;82(5):447-53.
6
Cirrhosis associated with methotrexate treatment of psoriasis.与甲氨蝶呤治疗银屑病相关的肝硬化。
JAMA. 1968 Nov 11;206(7):1515-20.
7
Hepatotoxicity of methotrexate in the treatment of psoriasis.
Arch Dermatol. 1971 Mar;103(3):250-61.
8
Cirrhosis caused by methotrexate in the treatment of psoriasis.甲氨蝶呤治疗银屑病所致的肝硬化。
Arch Dermatol. 1969 Nov;100(5):523-30.
9
Hepatotoxicity of long-term methotrexate therapy for psoriasis.
Arch Intern Med. 1973 Sep;132(3):391-6.
10
Liver injury associated with methotrexate therapy for psoriasis.
Mayo Clin Proc. 1973 Nov;48(11):787-92.